Immorta Bio completes preclinical studies for AI-designed senolytic peptide
Immorta Bio anticipates initial human evaluation before year-end 2026, but SenoMune-0257 has no established human safety or efficacy record and no trial start is confirmed.
By RuntimeWire Staff · Published
Primary source: PR Newswire
Why it matters
Immorta Bio is trying to make immune-based senolytic therapy easier to manufacture by replacing a personalized cell product with a synthetic peptide. Its planned move toward human testing will test both the biology and that product strategy.
Immorta Bio says it has completed planned preclinical studies of SenoMune-0257, an AI-designed nine-amino-acid peptide intended to train immune cells to remove senescent cells.…